Dose‐finding designs using a novel quasi‐continuous endpoint for multiple toxicities
Open Access
- 21 January 2013
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 32 (16), 2728-2746
- https://doi.org/10.1002/sim.5737
Abstract
The aim of a phase I oncology trial is to identify a dose with an acceptable safety profile. Most phase I designs use the dose‐limiting toxicity, a binary endpoint, to assess the unacceptable level of toxicity. The dose‐limiting toxicity might be incomplete for investigating molecularly targeted therapies as much useful toxicity information is discarded. In this work, we propose a quasi‐continuous toxicity score, the total toxicity profile (TTP), to measure quantitatively and comprehensively the overall severity of multiple toxicities. We define the TTP as the Euclidean norm of the weights of toxicities experienced by a patient, where the weights reflect the relative clinical importance of each grade and toxicity type. We propose a dose‐finding design, the quasi‐likelihood continual reassessment method (CRM), incorporating the TTP score into the CRM, with a logistic model for the dose–toxicity relationship in a frequentist framework. Using simulations, we compared our design with three existing designs for quasi‐continuous toxicity score (the Bayesian quasi‐CRM with an empiric model and two nonparametric designs), all using the TTP score, under eight different scenarios. All designs using the TTP score to identify the recommended dose had good performance characteristics for most scenarios, with good overdosing control. For a sample size of 36, the percentage of correct selection for the quasi‐likelihood CRM ranged from 80% to 90%, with similar results for the quasi‐CRM design. These designs with TTP score present an appealing alternative to the conventional dose‐finding designs, especially in the context of molecularly targeted agents. Copyright © 2013 John Wiley & Sons, Ltd.This publication has 34 references indexed in Scilit:
- Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugsInvestigational New Drugs, 2010
- An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New TherapeuticsClinical Cancer Research, 2010
- Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering CommitteeClinical Cancer Research, 2010
- Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agentsTargeted Oncology, 2010
- A comparison of model choices for the continual reassessment method in phase I cancer trialsStatistics in Medicine, 2009
- Model calibration in the continual reassessment methodClinical Trials, 2009
- Dose Escalation Methods in Phase I Cancer Clinical TrialsJNCI Journal of the National Cancer Institute, 2009
- Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified ApproachBiometrics, 2009
- Comparison of Isotonic Designs for Dose-FindingStatistics in Biopharmaceutical Research, 2009
- The continual reassessment method in cancer phase i clinical trials: A simulation studyStatistics in Medicine, 1993